Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Adverse Reactions to Biologics

Editor(s): Puig L. (Barcelona) 
Gulliver W. (St. John's, NL) 
Cover

Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab)

Hwang S.J.E.a, b · Fernández-Peñas P.a, b

Author affiliations

aDepartment of Dermatology, Westmead Hospital, Sydney, and bSydney Medical School, The University of Sydney, Sydney, Australia

Related Articles for ""

Puig L, Gulliver W (eds): Adverse Reactions to Biologics. Curr Probl Dermatol. Basel, Karger, 2018, vol 53, pp 82-92

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: November 07, 2017
Cover Date: 2018

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-318-06100-0 (Print)
eISBN: 978-3-318-06101-7 (Online)

Abstract

With increasing use of immunotherapies such as anti-cytotoxic T cell lymphocyte antigen-4 and anti-programmed cell death 1 antibodies, various skin toxicities have emerged. Severity of skin toxicities varies from mild lichenoid reaction to severe toxic epidermal necrolysis. Appropriate diagnosis and management of these skin toxicities are essential for optimal patient care and to avoid unnecessary cessation of anti-cancer therapies. This review summarises a wide range of cutaneous manifestations associated with immunotherapy usage in patients with metastatic melanoma.

© 2018 S. Karger AG, Basel


References

  1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
  2. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.
  3. Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C, et al: New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol 2016;12:57-75.
  4. Hwang SJ, Anforth R, Carlos G, Fernandez-Penas P: Cutaneous adverse events of new anti-melanoma therapies: classification and management. Actas Dermosifiliogr 2017;108:6-16.
  5. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al: Autoimmunity associated with immunotherapy of cancer. Blood 2011;118:499-509.
  6. Karimkhani C, Gonzalez R, Dellavalle RP: A review of novel therapies for melanoma. Am J Clin Dermatol 2014;15:323-337.
  7. Ribas A: Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 2010;37:450-454.
  8. Mavropoulos JC, Wang TS: Managing the skin toxicities from new melanoma drugs. Curr Treat Options Oncol 2014;15:281-301.
  9. Alatrash G, Jakher H, Stafford PD, Mittendorf EA: Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf 2013;12:631-645.
  10. Tosti G, Cocorocchio E, Pennacchioli E: Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clin Cosmet Investig Dermatol 2013;6:245-256.
  11. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010;21:1712-1717.
  12. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al: Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-164.
  13. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME: The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013;69:e121-e128.
  14. de Golian E, Kwong BY, Swetter SM, Pugliese SB: Cutaneous complications of targeted melanoma therapy. Curr Treat Options Oncol 2016;17:57.
  15. Lacouture ME, Wolchok JD, Yosipovitch G, Kahler KC, Busam KJ, Hauschild A: Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014;71:161-169.
  16. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, et al: Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 2014;53:376-384.
  17. Weber JS, Kahler KC, Hauschild A: Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-2697.
  18. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al: Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-384.
  19. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al: The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013;8:e53745.
  20. Hwang SJ, Carlos G, Wakade D, Sharma R, Fernandez-Penas P: Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma. Melanoma Res 2016;26:417-420.
  21. Pintova S, Sidhu H, Friedlander PA, Holcombe RF: Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013;23:498-501.
  22. Gormley R, Wanat K, Elenitsas R, Giles J, McGettigan S, Schuchter L, et al: Ipilimumab-associated sweet syndrome in a melanoma patient. J Am Acad Dermatol 2014;71:e211-e213.
  23. Kyllo RL, Parker MK, Rosman I, Musiek AC: Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol 2014;70:e85-e86.
  24. Rudolph BM, Staib F, Von Stebut E, Hainz M, Grabbe S, Loquai C: Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma - simultaneous occurrence of pyoderma gangrenosum and colitis. Eur J Dermatol 2014;24:268-269.
  25. Sheik Ali S, Goddard AL, Luke JJ, Donahue H, Todd DJ, Werchniak A, et al: Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015;151:195-199.
  26. Abdel-Rahman O, ElHalawani H, Fouad M: Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol 2015;11:2471-2484.
  27. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al: Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-622.
  28. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-6053.
  29. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13(22 pt 1):6681-6688.
  30. Ensslin CJ, Rosen AC, Wu S, Lacouture ME: Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 2013;69:708-720.
  31. Fecher LA, Agarwala SS, Hodi FS, Weber JS: Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013;18:733-743.
  32. Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, et al: Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012;13:1020-1024.
  33. Gangadhar TC, Vonderheide RH: Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 2014;11:91-99.
  34. Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A: Cutaneous adverse effects of targeted therapies: Part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 2015;72:221-236; quiz 237-238.
  35. Callahan MK, Postow MA, Wolchok JD: Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 2013;31:191-199.
  36. Spain L, Diem S, Larkin J: Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016;44:51-60.
  37. Choi JN: Dermatologic adverse events to chemotherapeutic agents, Part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg 2014;33:40-48.
  38. Munoz J, Guillot B, Girard C, Dereure O, Du-Thanh A: First report of ipilimumab-induced Grover disease. Br J Dermatol 2014;171:1236-1237.
  39. Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, et al: Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma. J Cutan Pathol 2016;43:787-791.
  40. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-547.
  41. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-988.
  42. Assi H, Wilson KS: Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases. Curr Oncol 2013;20:e165-e169.
  43. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al: Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015;33:773-781.
  44. Staser K, Chen D, Solus J, Rosman IS, Schaffer A, Cornelius L, et al: Extensive tumoral melanosis associated with ipilimumab-treated melanoma. Br J Dermatol 2016;175:391-393.
  45. Libon F, Arrese JE, Rorive A, Nikkels AF: Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases. Clin Exp Dermatol 2013;38:276-279.
  46. Nishimura H, Honjo T: PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 2001;22:265-268.
  47. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al: Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-144.
  48. Tsai KK, Zarzoso I, Daud AI: PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014;10:3111-3116.
  49. Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, et al: Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 2017;44:158-176.
  50. Postow MA: Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015:76-83.
  51. Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al: Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2016;27:1362.
  52. Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al: Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 2016;74:455-461.e1.
  53. Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al: Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016;60:12-25.
  54. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al: Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017;35:785-792.
  55. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al: Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-2532.
  56. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P: A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015;25:265-268.
  57. Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, et al: Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016;4:383-389.
  58. Jour G, Glitza IC, Ellis RM, Torres-Cabala CA, Tetzlaff MT, Li JY, et al: Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 2016;43:688-696.
  59. Wakade DV, Carlos G, Hwang SJ, Chou S, Hui R, Fernandez-Penas P: PD-1 inhibitors induced bullous lichen planus-like reactions: a rare presentation and report of three cases. Melanoma Res 2016;26:421-424.
  60. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al: Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015;151:1206-1212.
  61. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS: Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016;22:886-894.
  62. Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al: Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol 2016;152:45-51.
  63. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al: Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013;31:4311-4318.
  64. Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, et al: Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 2016;152:1128-1136.
  65. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al: Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384:1109-1117.
  66. Joseph RW, Cappel M, Goedjen B, Gordon M, Kirsch B, Gilstrap C, et al: Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy. Cancer Immunol Res 2015;3:18-22.
  67. Chou S, Hwang SJ, Carlos G, Wakade D, Fernandez-Penas P: Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on antiprogramed cell death-1 (anti-PD-1) therapy with or without ipilimumab. Am J Dermatopathol 2017;39:23-27.
  68. Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S, et al: Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 2016;43:339-346.
  69. Tripathi A, Kaymakcalan MD, LeBoeuf NR, Harshman LC: Programmed cell death-1 pathway inhibitors in genitourinary malignancies: specific side-effects and their management. Curr Opin Urol 2016;26:548-555.
  70. Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, et al: Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:190-209.
  71. Bonigen J, Raynaud-Donzel C, Hureaux J, Kramkimel N, Blom A, Jeudy G, et al: Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol 2017;31:e254-e257.
  72. Totonchy MB, Ezaldein HH, Ko CJ, Choi JN: Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol 2016;152:590-592.
  73. Kato Y, Otsuka A, Miyachi Y, Kabashima K: Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 2016;30:e89-e91.
  74. Matsumura N, Ohtsuka M, Kikuchi N, Yamamoto T: Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 2016;96:259-260.
  75. Ohtsuka M, Miura T, Mori T, Ishikawa M, Yamamoto T: Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol 2015;151:797-799.
  76. Chia PL, John T: Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC). J Immunother 2016;39:202-204.
  77. Hwang SJ, Carlos G, Chou S, Wakade D, Carlino MS, Fernandez-Penas P: Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Res 2016;26:413-416.
  78. Beck KM, Dong J, Geskin LJ, Beltrani VP, Phelps RG, Carvajal RD, et al: Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid. J Immunother Cancer 2016;4:20.
  79. Parakh S, Nguyen R, Opie JM, Andrews MC: Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma. Australas J Dermatol 2016, Epub ahead of print.
  80. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A: Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 2014;153:145-152.
  81. Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, et al: PD-1 is a novel regulator of human B-cell activation. Int Immunol 2013;25:129-137.
  82. Tetzlaff MT, Nagarajan P, Chon S, Huen A, Diab A, Omar P, et al: Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features. Am J Dermatopathol 2017;39:121-129.
  83. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
  84. van Tuyll van Serooskerken AM, van Marion AM, de Zwart-Storm E, Frank J, Poblete-Gutierrez P: Lichen planus with bullous manifestation on the lip. Int J Dermatol 2007;46(suppl 3):25-26.
  85. Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, et al: Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 2016;22:4023-4029.
  86. Nayar N, Briscoe K, Fernandez Penas P: Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory metastatic melanoma. J Immunother 2016;39:149-152.
  87. Sibaud V, David I, Lamant L, Resseguier S, Radut R, Attal J, et al: Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Res 2015;25:555-558.
  88. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al: Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-135.
  89. Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R: Pembrolizumab-associated sarcoidosis. JAAD Case Rep 2016;2:290-293.
  90. Khoja L, Maurice C, Chappell M, MacMillan L, Al-Habeeb AS, Al-Faraidy N, et al: Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016;4:175-178.
  91. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al: Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 2015;33:1430-1437.
  92. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al: Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015;21:4286-4293.
  93. Hwang SJ, Byth K, Fernandez-Penas P: Time-dependent measurement of adverse events. JAMA Dermatol 2015;151:1392.
  94. . Zhao CY, Hwang SJE, Wakade D, Carlos G, Anforth R, Carlino M, Fernandez-Penas P: Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: an observational study. Australas J Dermatol 2017, in press.
  95. Wolner ZJ, Marghoob AA, Pulitzer MP, Postow MA, Marchetti MA: A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol 2017, Epub ahead of print.
  96. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465.
  97. Sullivan RJ, Hamid O, Gonzalez R, et al: Safety and Clinical Activity of Atezolizumab + Cobimetinib + Vemurafenib in BRAFV600-Mutant Metastatic Melanoma. Boston, Society for Melanoma Research Annual Meeting, 2016.
  98. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-133.
  99. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: November 07, 2017
Cover Date: 2018

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISBN: 978-3-318-06100-0 (Print)
eISBN: 978-3-318-06101-7 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.